At the end of CMS' comment period, the American Society of Clinical Oncology submitted its comments and recommendations for the proposed changes.
In July this year, CMS made public proposed policy changes to the Medicare Physician Fee Schedule (PFS) with updates on payment policies, payment rates, and quality provisions. These are the first set of proposed changes after the Sustainable Growth Rate repeal and include important changes to the Physician Quality Reporting System, the Physician Value-Based Payment Modifier, and the Medicare Electronic Health Record Incentive Program.
In response to the proposed changes, the American Society of Clinical Oncology (ASCO)—in a letter submitted to CMS at the end of the public comment period—suggests that CMS should “reconsider revisions to payment policies that could be administratively burdensome to oncology practices and result in reimbursement that inadequately supports optimal cancer patient care.”
While agreeing with some of the policy changes, ASCO has drawn attention to certain provisions that would impact patient care, physician payment, and quality of care. The following are concerns and recommendations by the organization:
1. “Incident” to Billing. ASCO recommends that CMS should not implement its proposal to change the incident to rules without clarifying that the ordering physician may differ from the supervising physician for chemotherapy administration.
2. Potentially Misvalued Codes. ASCO recommends that CMS should use methodologies other than the "high expenditure by specialty screen" to identify potentially misvalued codes.
3. Cancer Staging Measure. ASCO recommends that CMS should not finalize its proposal to eliminate the cancer staging measure from registry reporting in the Physician Quality Reporting System. ASCO urges CMS to retain this measure and consider refining the measure to apply only to a period of time following the initial office visit.
4. Chronic Care Management. ASCO recommends that chronic care management services have the potential to provide meaningful opportunities to improve oncology care management and lower Medicare's overall expenditures. CMS should continue to focus resources on providing beneficiaries with access to medical advice and eliminating counterproductive administrative burdens on providers that hamper patient access.
Additionally, ASCO has recommended CMS to reconsider the valuation of radiation oncology services to allow continued patient access to those services, particularly in the community clinics. For biosimilar products, ASCO has proposed fair and adequate reimbursement by CMS to allow patient access to these biologicals at lower cost.
In the letter, ASCO applauds the CMS proposal to provide reimbursement for advance care planning, with the flexibility of seeking advice from multiple providers. ASCO has recommended that CMS should establish new codes and payments for cognitive services performed in oncology care, which the CMS has recognized as an important task performed by specialists who care for certain subsets of Medicare beneficiaries. Other suggestions address tailoring quality and value measures for oncology and implementing alternate payment models to improve quality while reducing cost of care.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More